Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
Peter C. Taylor, Marco Matucci‐Cerinic, Rieke Alten, et al.
Therapeutic Advances in Musculoskeletal Disease (2022) Vol. 14
Open Access | Times Cited: 24

Showing 24 citing articles:

Current pharmacological therapy for rheumatoid arthritis, factors for its effectiveness and associated complications: systematic review
Jonathan Rocha
Interdisciplinary Rehabilitation / Rehabilitacion Interdisciplinaria (2024) Vol. 4, pp. 76-76
Open Access | Times Cited: 17
Exploring the mechanism of Celastrol in the treatment of rheumatoid arthritis based on systems pharmacology and multi-omics
Liuting Zeng, Ganpeng Yu, Kailin Yang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis
Peter Youssef, Sabina Ciciriello, Talib Tahir, et al.
Rheumatology and Therapy (2025)
Open Access
PEPITEM, its tripeptide pharmacophores and their peptidomimetic analogues regulate the inflammatory response through parenteral and topical dosing in models of peritonitis and psoriasis
Anella Saviano, Bonita Apta, Samantha Tull, et al.
Pharmacological Research (2025) Vol. 213, pp. 107624-107624
Open Access
Transition from reference adalimumab to biosimilar SB5 in patients with rheumatoid arthritis: sub-analysis of Spanish patients in the PROPER study
Fernando Perez‐Ruiz, B Paret, Eugenio Chamizo Carmona
Exploration of Musculoskeletal Diseases (2025)
Closed Access
Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis
Tsutomu TOGASHI, Ryuhei Ishihara, Ryu Watanabe, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 5, pp. 1529-1529
Open Access
Combined healthy lifestyle score and odds of rheumatoid arthritis in Iranian adults: a nested case–control from PERSIAN Dena Cohort Study (PDCS)
Javad Harooni, Abdollah Pourjavid, Farshad Amirkhizi, et al.
BMJ Open (2025) Vol. 15, Iss. 3, pp. e097715-e097715
Open Access
Primary non-response in inflammatory arthritis treated with biologics and targeted therapies in daily clinical practice
Leticia León, D. Freites, Esther Toledano, et al.
Therapeutic Advances in Musculoskeletal Disease (2025) Vol. 17
Open Access
Therapeutic potential of Coptis chinensis for arthritis with underlying mechanisms
Mengyuan Li, Fei Tian, Jinling Guo, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor
Roberto Caporali, Aditi Kadakia, O. Howell, et al.
Advances in Therapy (2024) Vol. 41, Iss. 9, pp. 3706-3721
Open Access | Times Cited: 3
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
Peter C. Taylor, A. Askari, Ernest Choy, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 4
What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?
Peter C. Taylor, Eugen Feist, Janet Pope, et al.
Therapeutic Advances in Musculoskeletal Disease (2024) Vol. 16
Open Access | Times Cited: 1
Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)
А. А. Баранов, I. B. Vinogradova, О. Н. Аношенкова, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 3, pp. 307-319
Open Access | Times Cited: 3
Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
А. O. Bobkova, А. М. Лила
Modern Rheumatology Journal (2023) Vol. 17, Iss. 3, pp. 82-88
Open Access | Times Cited: 2
Factors Influencing Adalimumab Treatment Response in Patients with Rheumatoid Arthritis: The Future of Clinical Expertise
Samer Imad Mohammed, Ali L. Jasim, Mohammed Jamal Yawuz, et al.
Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) (2023) Vol. 5, pp. 192-204
Open Access | Times Cited: 2
Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
А. O. Bobkova, А. М. Лила, А. Е. Каратеев
Modern Rheumatology Journal (2024) Vol. 18, Iss. 4, pp. 16-22
Open Access
PEPITEM Tripeptides and Peptidomimetics: Next-Generation Modulators of Inflammation in Immune-Mediated Conditions
Anella Saviano, Bonita Apta, Samantha Tull, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Therapeutic drug monitoring for immune mediated inflammatory diseases
Neil Chanchlani, Z.Z.N. Yiu, Lisa K. Stamp, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e001130-e001130
Open Access
Infiltrations of plasma cells in synovium predict inadequate response to Adalimumab in Rheumatoid Arthritis patients
Jian‐Bin Li, Peng Cheng Liu, Liming Chen, et al.
Arthritis Research & Therapy (2024) Vol. 26, Iss. 1
Open Access
Increasing Trends in the Pancreatitis Risk With Tumor Necrosis Factor Inhibitor Use
Joyce H Gu, Mark Samarneh
Cureus (2024)
Open Access
Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet’S Desease
N. Barroso García, J. L. Martín-Varillas, Iván Ferraz‐Amaro, et al.
(2024)
Closed Access
Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet’s Disease
Nuria Barroso-García, J. L. Martín-Varillas, Iván Ferraz‐Amaro, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 23, pp. 7388-7388
Open Access
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis
Clément Triaille, Pierre Quartier, Lien De Somer, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 3, pp. 594-607
Open Access
The Role Of Biologic Therapies In Improving Joint Health In Autoimmune Arthritis
Shayim Saud Alanazi, Ibrahim Hassan Almalki, Abdulaziz Amin Alandijani, et al.
Journal of Survey in Fisheries Sciences (2023)
Open Access
Page 1

Scroll to top